



Figure 1

*Radioligand binding results (IC₅₀ values)
for certain compounds of the present invention*



3

IC₅₀ values

D_{2L} (human) < 500 nM
D_{4.4} (human) > 1 μ M
5HT_{1A} (human) < 500 nM
5HT_{2A} (human) < 100 nM
5HT_{2B} (human) < 100 nM
5HT_{2C} (human) < 100 nM
alpha_{1A} (rat) < 100 nM
alpha_{1D} (human) < 100 nM
alpha_{2A} (human) < 1 μ M


4

IC₅₀ values

D_{2L} (human) < 500 nM
5HT_{2A} (human) < 100 nM
5HT_{2B} (human) < 10 nM
5HT_{2C} (human) < 500 nM

Figure 2


*Radioligand binding results (IC₅₀ values)
for certain compounds of the present invention*



5

IC₅₀ values

D_{2L} (human) < 5 μ M
5HT_{2A} (human) < 10 nM
5HT_{2B} (human) < 10 nM
5HT_{2C} (human) < 10 nM





6

IC₅₀ values

D_{2L} (human) < 5 μ M
5HT_{2A} (human) < 10 nM
5HT_{2B} (human) < 100 nM
5HT_{2C} (human) < 10 nM

Figure 3

*Radioligand binding results (IC₅₀ values)
for certain compounds of the present invention*



7


IC₅₀ values
D_{2L} (human) > 1 μ M
D₃ (human) < 1 μ M
5HT₁ (rat) > 1 μ M
5HT_{1A} (human) < 500 nM
5HT₂ (rat) < 100 nM
5HT_{2A} (human) < 10 nM
5HT_{2B} (human) < 100 nM
5HT_{2C} (human) < 100 nM

8

IC₅₀ values
D_{2L} (human) < 1 μ M
D₃ (human) < 1 μ M
5HT₁ (rat) > 1 μ M
5HT_{1A} (human) < 1 μ M
5HT₂ (rat) < 100 nM
5HT_{2A} (human) < 10 nM
5HT_{2B} (human) < 100 nM
5HT_{2C} (human) < 10 nM

Figure 4


*Radioligand binding results (IC₅₀ values)
for certain compounds of the present invention*



9

IC₅₀ values

D_{2L} (human) < 1 μ M
D₃ (human) < 500 nM
D_{4.4} (human) > 1 μ M
5HT_{1A} (human) < 500 nM
5HT_{2A} (human) < 500 nM
5HT_{2B} (human) < 100 nM
5HT_{2C} (human) < 500 nM
5HT₆ (human) > 1 μ M
alpha_{1A} (rat) < 1 μ M
alpha_{1D} (human) > 1 μ M
alpha_{2A} (human) > 1 μ M




11

IC₅₀ values

D_{2L} (human) < 1 μ M
D_{2S} (human) < 1 μ M
D₃ (human) < 1 μ M
D_{4.4} (human) > 1 μ M
5HT₂ (rat) > 1 μ M
5HT₃ (human) > 1 μ M
5HT₆ (human) > 1 μ M
5HT₇ (human) < 1 μ M

Figure 5


*Radioligand binding results (IC₅₀ values)
for certain compounds of the present invention*



13

IC₅₀ values

D_{2L} (human) < 500 nM
5HT_{2A} (human) < 100 nM
5HT_{2B} (human) < 100 nM
5HT_{2C} (human) < 500 nM
alpha_{1A} (rat) > 1 μM
alpha_{1D} (human) < 500 nM
alpha_{2A} (human) < 1 μM





14

IC₅₀ values

D_{2L} (human) < 500 nM
5HT_{2A} (human) < 500 nM
5HT_{2B} (human) < 100 nM
5HT_{2C} (human) < 500 nM
alpha_{1A} (rat) < 100 nM
alpha_{1D} (human) < 100 nM
alpha_{2A} (human) < 1 μM

Figure 6

*Radioligand binding results (IC₅₀ values)
for certain compounds of the present invention*



15

IC₅₀ values

NE Transporter (human) <500 nM
D_{2L} (human) <500 nM
D₃ (human) <500 nM
DA Transporter (human) <100 nM
5-HT₇ (human) <500 nM
5-HT Transporter (human) >1 μM

16

IC₅₀ values

alpha 1 (rat) <1 μM
alpha 2 (rat) <1 μM
D_{2L} (human) <1 μM
D_{2S} (human) >1 μM
D₃ (human) <1 μM
D_{4,4} (human) >1 μM
5-HT₇ (human) <1 μM
5-HT_{2A} (human) <1 μM